This document is a Form 10-Q, a quarterly report filed by Eli Lilly and Company with the U.S. Securities and Exchange Commission for the period ending June 30, 2025. It provides a comprehensive financial overview, including statements of operations, balance sheets, and cash flows, alongside detailed notes explaining the accounting principles and significant financial activities. The report also addresses business developments, such as updates on their clinical development pipeline for various pharmaceutical products, recent acquisitions, and an extensive discussion of legal proceedings and risk factors, notably concerning drug pricing, intellectual property, and regulatory compliance. Overall, the document aims to give investors a transparent look into the company's financial health, operational performance, and future outlook.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related